secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-06-30T23:59:59+00:00
Accession:  0001404644-25-000070
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene announces FDA agreement on registrational trial design for NGN-401 gene therapy in Rett syndrome
--------------------------------------------------------------------------------

- FDA agreed on single-arm, open-label, baseline-controlled design; N=18 proposed; primary endpoint: CGI-I improvement plus gain of developmental milestone.
- Phase 1/2 fully enrolled; 5 participants dosed in 1H2025; no HLH/hyperinflammatory syndrome observed at 1E15 vg dose.
- First four participants achieved 23 developmental milestones across hand function, communication, and ambulation by 3–15 months.
- Cash, cash equivalents & investments of $292.6M as of March 31, 2025; runway extended into early 2028.
- Updated efficacy and safety data expected in second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000070/0001404644-25-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000070/ngne-20250630.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer